Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina
Public ClinicalTrials.gov record NCT00353067. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Veliflapon (DG-031) in Reducing the Risk of Acute Cardiovascular Events in African American Patients With Coronary Artery Disease(The LTCAD Study).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if veliflapon (DG-031)can prevent a heart attack or stroke in African American patients with a history of unstable angina or myocardial infarction.
Study identification
- NCT ID
- NCT00353067
- Recruitment status
- Suspended
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 3,450 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 35 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2006
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Nov 28, 2006
Started 2006
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Montgomery | Alabama | 36106 | — |
| Not listed | Jacksonville | Florida | 32216 | — |
| Not listed | Melrose Park | Illinois | 60160 | — |
| Not listed | Oklahoma City | Oklahoma | 73103 | — |
| Not listed | Philadelphia | Pennsylvania | 19142 | — |
| Not listed | Nashville | Tennessee | 37203 | — |
| Not listed | Carrollton | Texas | 75007 | — |
| Not listed | Fort Worth | Texas | 76104 | — |
| Not listed | Richardson | Texas | 75080 | — |
| Not listed | Hopewell | Virginia | 23860 | — |
| Not listed | Suffolk | Virginia | 23434 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00353067, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 28, 2006 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00353067 live on ClinicalTrials.gov.